A 2-Year, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase II-III Study to Evaluate the Efficacy and Safety of Oral Ranirestat (40 and 80 mg) in Mild to Moderate Diabetic Sensorimotor Polyneuropathy.

Trial Profile

A 2-Year, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase II-III Study to Evaluate the Efficacy and Safety of Oral Ranirestat (40 and 80 mg) in Mild to Moderate Diabetic Sensorimotor Polyneuropathy.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs Ranirestat (Primary)
  • Indications Diabetic neuropathies; Polyneuropathy
  • Focus Registrational; Therapeutic Use
  • Sponsors Eisai Inc
  • Most Recent Events

    • 01 Feb 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 28 Nov 2012 Planned end date changed from 1 May 2013 to 1 Jan 2013 as reported by ClinicalTrials.gov.
    • 14 Feb 2012 Additional trial location (Belgium) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top